Pfizer, others seek untapped potential in virtual clinical trials

Drugmakers have widely acknowledged that they need to streamline their R&D processes, and many have embarked on the use of digital technologies to improve the efficiency of the clinical development process. In an article in Life Science Leader, Pfizer's Craig Lipset talked about how the company's virtual clinical trial rolled out many new tech tools at once to trial the overall bladder drug Detrol, with some setbacks along the way. But the drug giant ($PFE) will resume the virtual program next year. Article